sur Galimedix, Inc.
Galimedix Therapeutics Assembles Scientific Advisory Board for Phase 2 Study of GAL-101
Galimedix Therapeutics, Inc. has announced the formation of a Scientific Advisory Board (SAB) composed of retina experts from both clinical practice and academia. This move comes as the company prepares to initiate Phase 2 clinical trials for its lead compound, GAL-101, aimed at treating dry age-related macular degeneration (AMD).
The SAB includes notable figures from the ophthalmology sector, such as Dr. Konstantinos Balaskas (UCL Institute of Ophthalmology, UK), Dr. Justis P. Ehlers (Cole Eye Institute, USA), and others. Their expertise will guide the development of GAL-101 eye drops, which have shown promise in preclinical and Phase 1 studies.
The advisory board convened at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to discuss the design and endpoints of the Phase 2 DREAM trial, expected to start in late 2024.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Galimedix, Inc.